Answers are grounded in this paper and cite their sources.
To realize the potential of genome engineering therapeutics, tractable strategies must be identified that balance personalized therapy with the need for off-the-shelf availability. We hypothesized that regional clustering of pathogenic variants can inform the design of rational prime editing therapeutics to treat the majority of genetic cardiovascular diseases with a limited number of reagents.
No takes yet. Share an insight, caveat, or question.
Krysov et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: